O'Connor P C, Finch M J, Harron D W, Meredith P A, McDevitt D G, Shanks R G
Br J Clin Pharmacol. 1985 Dec;20(6):659-67. doi: 10.1111/j.1365-2125.1985.tb05125.x.
The effects of single oral doses of bucindolol (50, 100, 200 and 400 mg), pindolol (10 mg), propranolol (160 mg) and placebo on arterial pressure and heart rate in the supine and standing positions and exercise heart rate were compared in 12 healthy male volunteers. Supine heart rate was significantly greater after all four doses of bucindolol and pindolol in comparison to propranolol. Bucindolol had no significant effect on standing heart rate which was significantly reduced by pindolol and propranolol. Bucindolol, pindolol and propranolol significantly reduced an exercise tachycardia for at least 24 h after drug administration. Supine systolic pressure was not affected by any treatment but supine diastolic pressure was significantly reduced by bucindolol (200 and 400 mg) and by pindolol. All doses of bucindolol, propranolol and pindolol significantly reduced standing systolic blood pressure. There was a significant linear trend for reductions in standing systolic blood pressure and increasing doses of bucindolol. Standing diastolic blood pressure was significantly reduced by bucindolol 200 and 400 mg. Faintness and light headedness occurred in 6 of 12 subjects after 200 mg bucindolol and in 8 of 10 subjects after 400 bucindolol. After bucindolol, analysis of plasma samples demonstrated the presence of bucindolol, 5-hydroxy and 6-hydroxy bucindolol and indolyl-t-butylamine. These observations indicate that in man, bucindolol is a beta-adrenoceptor blocking drug with hypotensive activity and probably partial agonist activity. It is unlikely that the hypotensive effects result from blockade of beta-adrenoceptors or from the drug's partial agonist activity.
在12名健康男性志愿者中,比较了单次口服布新洛尔(50、100、200和400毫克)、吲哚洛尔(10毫克)、普萘洛尔(160毫克)和安慰剂对仰卧位和站立位动脉压、心率以及运动心率的影响。与普萘洛尔相比,所有四种剂量的布新洛尔和吲哚洛尔服用后仰卧位心率显著更高。布新洛尔对站立位心率无显著影响,而吲哚洛尔和普萘洛尔可使其显著降低。布新洛尔、吲哚洛尔和普萘洛尔在给药后至少24小时内可显著降低运动性心动过速。仰卧位收缩压不受任何治疗影响,但布新洛尔(200和400毫克)和吲哚洛尔可使仰卧位舒张压显著降低。所有剂量的布新洛尔、普萘洛尔和吲哚洛尔均显著降低站立位收缩压。站立位收缩压降低与布新洛尔剂量增加呈显著线性趋势。布新洛尔200和400毫克可使站立位舒张压显著降低。12名受试者中有6名在服用200毫克布新洛尔后、10名受试者中有8名在服用400毫克布新洛尔后出现头晕和轻度眩晕。服用布新洛尔后,血浆样本分析显示存在布新洛尔、5-羟基和6-羟基布新洛尔以及吲哚基叔丁胺。这些观察结果表明,在人体中,布新洛尔是一种具有降压活性且可能具有部分激动剂活性 的β-肾上腺素能受体阻滞剂。降压作用不太可能是由β-肾上腺素能受体阻断或药物的部分激动剂活性所致。